DeutschNewstral
Article
bizjournals.com on 2016-04-22 22:46
Chapel Hill biotech gets FDA green light to test heart disease therapy
Related news
- Chapel Hill gene therapy startup raises $50Mbizjournals.com
- WRaleigh biotech startup receives FDA approval for testosterone therapywraltechwire.com
- FDA approves Horsham biotech firm’s drug for Crohn’s diseasebizjournals.com
- FDA grants rare pediatric disease designation to RegenxBio gene therapybizjournals.com
- DFDA approves CRISPR gene therapy trials for sickle cell diseasedailycal.org
- First therapy for childhood aging disease wins FDA approvalbizjournals.com
- FDA approves Incyte's Jakafi as graft-versus-host disease therapybizjournals.com
FDA OKs first gene therapy for hereditary diseaseengadget
FDA approves first gene therapy for an inherited diseaseWashington Post- Biotech delays U.S. gene therapy launch due to outbreak, FDA discordbizjournals.com
- Bucks County biotech gets FDA approval to begin mid-stage testing of experimental Covid-19 therapybizjournals.com
Dallas-based biotech firm Taysha drops gene therapy following FDA meetingDallas News
Art therapy helps school cope with loss of Chapel Hill shooting victimsWRAL- A rare win: North Bay biotech gets FDA approval for drug to treat bone diseasebizjournals.com
South Side biotech gets FDA approval for drug to treat skin diseasepost-gazette.com
FDA Approves Two Gene Therapies to Treat Sickle Cell Disease Including a CRISPR-Based Therapyjdsupra.com- FDA Approves the First Gene Therapy to Treat an Inherited Diseasejdsupra.com
- FDA grants two key designations to Passage Bio's experimental Krabbe disease therapybizjournals.com
- TThis gene-editing therapy could cure sickle cell disease, and it’s close to FDA approvalthehill.com
- MSpark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye diseasemarketwatch.com